Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants (Q33404251)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants (English)

1 reference

Europe PubMed Central

26 July 2017

Gloria Samperiz

object named as

Gloria Sampériz

10

0 references

object named as

Teresa Auguet

9

0 references

object named as

Francesc Vidal

1

0 references

author name string

Miguel López-Dupla

2

1 reference

Europe PubMed Central

26 July 2017

Montserrat Laguno

3

1 reference

Europe PubMed Central

26 July 2017

Sergi Veloso

4

1 reference

Europe PubMed Central

26 July 2017

Josep Mallolas

5

1 reference

Europe PubMed Central

26 July 2017

Javier Murillas

6

1 reference

Europe PubMed Central

26 July 2017

Carmen Cifuentes

7

1 reference

Europe PubMed Central

26 July 2017

Lluis Gallart

8

1 reference

Europe PubMed Central

26 July 2017

Antoni Payeras

11

1 reference

Europe PubMed Central

26 July 2017

Pilar Hernandez

12

1 reference

Europe PubMed Central

26 July 2017

Mireia Arnedo

13

1 reference

Europe PubMed Central

26 July 2017

Josep Ma Gatell

14

1 reference

Europe PubMed Central

26 July 2017

Cristóbal Richart

15

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

2 November 2012

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

7

1 reference

Europe PubMed Central

26 July 2017

11

1 reference

Europe PubMed Central

26 July 2017

e47725

1 reference

Europe PubMed Central

26 July 2017

copyright license

Creative Commons Attribution 4.0 International

2 November 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Boceprevir and telaprevir in the management of hepatitis C virus-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

CCL5: a double-edged sword in host defense against the hepatitis C virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Upregulation of SOCS-3 and PIAS-3 Impairs IL-12-Mediated Interferon-Gamma Response in CD56+ T Cells in HCV-Infected Heroin Users

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Interferon signalling network in innate defence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Genetic deletion of murine SPRY domain-containing SOCS box protein 2 (SSB-2) results in very mild thrombocytopenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Haploview: analysis and visualization of LD and haplotype maps

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

A comparison of bayesian methods for haplotype reconstruction from population genotype data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

A New Statistical Method for Haplotype Reconstruction from Population Data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

21 June 2018

Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

Association ofCTLA4Polymorphisms with Sustained Response to Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Infection

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0047725

21 January 2018

Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487790

31 October 2018

Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa

1 reference

https://pubmed.ncbi.nlm.nih.gov/23133602

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0047725

1 reference

Europe PubMed Central

26 July 2017

2012PLoSO...747725V

0 references

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33404251&oldid=1866277625"